Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01317199 · ClinicalTrials.gov registry record · Phase 1
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
A Phase 1 study of Prostate Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 143
- Enrollment target
- 8
- Study locations
NCT01317199 is a Phase 1 study of Prostate Cancer that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 143 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (76% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT01317199, a Phase 1 study of Prostate Cancer, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 143 participants
- Enrollment target
- 8
- Study locations
Study Summary
This research is being done to test an investigational product called Muscadine Plus in the treatment of men who have received initial therapy (surgery and or radiation, cryotherapy or brachytherapy) for prostate cancer and are experiencing a rise in their prostate-specific antigens (PSA) level.
Conditions Studied
Interventions
- DRUG Placebo oral capsule
- DRUG Muscadine Plus Grape Skin Extract
- DRUG Low-dose MPX
- DRUG High-dose MPX
Study Locations (8)
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
- Howard University College of Medicine - Washington D.C.
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Maryland
- Johns Hopkins Hospital - Baltimore
Michigan
- Karmanos Cancer Institute - Detroit
New Jersey
- Cancer Institute of New Jersey - New Brunswick
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2011-07 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01317199
The ClinicalTrials.gov registry entry for NCT01317199 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (76% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Placebo oral capsule is the first listed.
NCT01317199 reports 8 study locations spanning 6 distinct geographic areas - top geographies include District of Columbia, Massachusetts, Maryland.
Frequently Asked Questions
What is clinical trial NCT01317199 about?
NCT01317199 is a clinical study titled "Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer". This research is being done to test an investigational product called Muscadine Plus in the treatment of men who have received initial therapy (surgery and or radiation, cryotherapy or brachytherapy) for prostate cancer and are experiencing a rise in their prostate-specific antigens (PSA) level.
What is the current status of trial NCT01317199?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 143 participants. The study started on 2011-07. Estimated completion is 2015-11.
What conditions does trial NCT01317199 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT01317199?
The interventions under investigation include: Placebo oral capsule (DRUG), Muscadine Plus Grape Skin Extract (DRUG), Low-dose MPX (DRUG), High-dose MPX (DRUG).
Who is sponsoring clinical trial NCT01317199?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01317199 being conducted?
This trial has 8 study locations across District of Columbia, Maryland, Massachusetts, Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.